Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward
- PMID: 26813738
- PMCID: PMC4727332
- DOI: 10.1186/s12961-016-0080-9
Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward
Abstract
Background: Dissemination bias occurs when only some results emerging from clinical research reach their intended audience in the knowledge translation process. Given that coverage decisions increasingly rely on evidence, it is important to explore the types of evidence considered. This paper aimed to examine the evidence base used by regulatory institutions involved in pricing and reimbursement of pharmaceuticals in a broad range of European countries, as well as their awareness of and approach towards dissemination bias.
Methods: A mixed methods approach was adopted. Regulatory documents and published literature were identified in systematic searches and relevant documents were analysed. An online survey was carried out to verify and expand insights.
Results: Forty-two relevant regulatory documents and 10 publications were included. The survey had a 35% response rate, yielding valid responses for 13 countries. A fragmented impression was obtained for most countries indicating a general lack of transparency regarding both processes of decision-making and approaches towards unpublished information. Dissemination bias was rarely consistently considered. Practices for the identification and inclusion of all available evidence varied considerably, as did the influence of missing evidence on decision-making. Differences were often attributable to the regulatory context and/or institutional principles.
Conclusions: Best practice is difficult to generalize given the identified variations. Individual exemplary practices support the necessity for institutional exchange at international level. Increased institutional commitment to transparency of methods and processes should be advocated.
Figures
Similar articles
-
From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.Health Res Policy Syst. 2015 Sep 25;13:39. doi: 10.1186/s12961-015-0028-5. Health Res Policy Syst. 2015. PMID: 26407728 Free PMC article.
-
A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.Value Health. 2014 Jan-Feb;17(1):98-108. doi: 10.1016/j.jval.2013.10.008. Value Health. 2014. PMID: 24438723
-
Procedures and methods of benefit assessments for medicines in Germany.Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5. Eur J Health Econ. 2008. PMID: 18987905
-
A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.Healthc Policy. 2015 May;10(4):24-46. Healthc Policy. 2015. PMID: 26142357 Free PMC article. Review.
-
Evidence for Health II: Overcoming barriers to using evidence in policy and practice.Health Res Policy Syst. 2016 Mar 14;14:17. doi: 10.1186/s12961-016-0086-3. Health Res Policy Syst. 2016. PMID: 26975200 Free PMC article. Review.
Cited by
-
Utilization of innovative medical technologies in German inpatient care: does evidence matter?Health Res Policy Syst. 2023 Oct 2;21(1):100. doi: 10.1186/s12961-023-01047-w. Health Res Policy Syst. 2023. PMID: 37784100 Free PMC article. Review.
-
The Assessment of the Innovativeness of a New Medicine in Italy.Front Med (Lausanne). 2021 Dec 8;8:793640. doi: 10.3389/fmed.2021.793640. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34957163 Free PMC article.
-
Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.BMJ Open. 2021 Oct 6;11(10):e051812. doi: 10.1136/bmjopen-2021-051812. BMJ Open. 2021. PMID: 34615680 Free PMC article.
-
Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".Int J Health Policy Manag. 2021 Mar 14;10(4):232-236. doi: 10.34172/ijhpm.2020.145. Int J Health Policy Manag. 2021. PMID: 32772012 Free PMC article.
References
-
- Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess. 2000;4:1–115. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
